Abstract | BACKGROUND AND OBJECTIVE: Approximately one-third of children with ulcerative colitis will experience at least 1 attack of acute severe colitis (ASC) before 15 years of age. Severe disease can be defined in children when Pediatric Ulcerative Colitis Activity Index is >65 and/or ≥6 bloody stools per day, and/or 1 of the following: tachycardia, fever, anemia, and elevated erythrocyte sedimentation rate with or without systemic toxicity. Our aim was to provide practical suggestions on the management of ASC in children. The goal of medical therapy is to avoid colectomy while preventing complications of disease, side effects of medications, and mortality. METHODS: RESULTS: CONCLUSIONS: Several pitfalls may be present in the management of ASC, and a correct clinical and therapeutic approach is recommended to reduce surgical risk.
|
Authors | Claudio Romano, Sana Syed, Simona Valenti, Subra Kugathasan |
Journal | Pediatrics
(Pediatrics)
Vol. 137
Issue 5
(05 2016)
ISSN: 1098-4275 [Electronic] United States |
PMID | 27244779
(Publication Type: Journal Article, Review)
|
Copyright | Copyright © 2016 by the American Academy of Pediatrics. |
Chemical References |
- Adrenal Cortex Hormones
- Biological Products
- Calcineurin Inhibitors
- Gastrointestinal Agents
- Immunosuppressive Agents
- Cyclosporine
- Infliximab
- Tacrolimus
|
Topics |
- Adrenal Cortex Hormones
(therapeutic use)
- Biological Products
(therapeutic use)
- Calcineurin Inhibitors
(therapeutic use)
- Child
- Colitis, Ulcerative
(classification, drug therapy)
- Cyclosporine
(therapeutic use)
- Drug Therapy, Combination
- Gastrointestinal Agents
(therapeutic use)
- Hospitalization
- Humans
- Immunosuppressive Agents
(adverse effects, therapeutic use)
- Infliximab
(therapeutic use)
- Severity of Illness Index
- Tacrolimus
(therapeutic use)
|